株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ジェネリック医薬品の世界市場予測:2019~2029年

Generic Drugs Market Forecast 2019-2029: Growth in Leading Regional and National Markets, Teva, Novartis, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy's Laboratories Limited, Apotex

発行 Visiongain Ltd 商品コード 220569
出版日 ページ情報 英文 246 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=146.78円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

Back to Top
ジェネリック医薬品の世界市場予測:2019~2029年 Generic Drugs Market Forecast 2019-2029: Growth in Leading Regional and National Markets, Teva, Novartis, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy's Laboratories Limited, Apotex
出版日: 2019年06月14日 ページ情報: 英文 246 Pages
概要

世界のジェネリック医薬品市場は、2018年に2573億米ドルの規模に達しました。更に、2019年から2029年にかけて、8.8%のCAGR (複合年間成長率) で拡大することが予測されています。世界市場の31%をアジア太平洋地域諸国が占めています。

当レポートでは、世界のジェネリック医薬品市場について分析し、市場の基本構造や背景事情 (関連規制など)、主な市場促進・抑制要因、市場規模・シェアの動向見通し、地域別/主要国市場の詳細動向、大手企業のプロファイルなどを調査しております。

第1章 レポートの概要

第2章 イントロダクション:ジェネリック医薬品

  • ジェネリック医薬品の台頭:概要
  • ジェネリック医薬品 (後発医薬品) とは何か?
    • 後発有効成分
  • 製薬産業の概略
    • ジェネリック医薬品の沿革
    • ハッチ=ワックスマン法 (Hatch-Waxman Act):ジェネリック医薬品の誕生
  • 生物学的同等性の実証:ジェネリック医薬品認証の主要な要因
  • ジェネリック医薬品の種類
  • 合成ジェネリック医薬品
  • ジェネリック医薬品市場の分類 - オーソライズド/ブランド/非ブランド
  • ジェネリック医薬品は、大手製薬企業にとって悪いニュースか?
    • 製薬業界の「エバーグリーニング戦略」
  • ジェネリック医薬品に対する規制 (米国・欧州・日本・中国)
  • 強制実施権
  • 市場の定義と分析の範囲

第3章 ジェネリック医薬品市場の将来予測

  • 世界のジェネリック医薬品市場:概要
  • 世界のジェネリック医薬品市場の拡大傾向
  • 世界市場の売上高見通し (今後11年間分)
  • 地域別の売上高見通し (今後11年間分)
    • 地域別シェアの動向見通し (今後11年間分)
  • 市場成長の牽引役となる国/市場
  • 国別シェアの動向見通し (今後11年間分)
  • 市場促進・抑制要因

第4章 北米のジェネリック医薬品市場

  • 市場概要
  • 市場促進・抑制要因
  • 市場予測 (今後11年間分)
  • 域内で活動する主要企業
  • ジェネリック医薬品市場の戦略的分析
  • 米国市場:成長促進要因
  • カナダ市場:成長促進要因
  • 市場シェア分析

第5章 欧州のジェネリック医薬品市場

  • 市場概要
  • 市場予測 (今後11年間分)
  • ドイツ市場
  • 英国市場
  • フランス市場
  • イタリア市場
  • スペイン市場
  • 市場シェア分析

第6章 アジア太平洋地域のジェネリック医薬品市場

  • 市場概要
  • インド市場
    • 主要企業
    • 売上高の予測 (今後11年間分)
    • 市場動向 (各種規制・規制・改革など)
  • 中国市場
  • 日本市場
  • オーストラリア市場
  • 韓国市場
  • 市場シェア分析

第7章 中東・アフリカのジェネリック医薬品市場

  • 市場概要
  • 南アフリカ市場
    • 売上高の予測 (今後11年間分)
  • サウジアラビア市場
  • アラブ首長国連邦 (UAE) 市場
  • 市場シェア分析

第8章 ラテンアメリカのジェネリック医薬品市場

  • 市場概要
  • ブラジル市場
    • 売上高の予測 (今後11年間分)
  • アルゼンチン市場
  • メキシコ市場
  • 市場シェア分析

第9章 ジェネリック医薬品市場の代表的企業

  • 継続的な成長と競争
  • Teva Pharmaceuticals Industries Limited
    • 企業沿革と業績分析 (過去5年間分)
    • 売上高の予測 (今後11年間分)
    • 製品ポートフォリオ
    • 近年の戦略展開の動き (企業合併・買収 (M&A) など)
  • Novartis
  • Mylan
  • Pfizer
  • Abbott
  • Aspen
  • Fresenius Kabi
  • Sanofi
  • Dr. Reddy's Laboratories Limited
  • Apotex, Inc.

第10章 ジェネリック医薬品市場の定性分析

  • 世界市場を左右する要因
  • 世界のジェネリック医薬品市場:SWOT分析
  • ポーターのファイブフォース分析

第11章 結論

付録

図表

List of Tables

  • Table 2.1 Types of Drug Names, 2018
  • Table 3.1 The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Regional and National Markets, 2018 and 2019
  • Table 3.2 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 3.3 The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2018-2029
  • Table 3.4 The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2018, 2023, and 2029
  • Table 3.5 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2018-2023, 2023-2029, 2018-2029
  • Table 3.6 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2018, 2023, and 2029
  • Table 4.1 North America Generic Drugs Market: by Country Value ($bn), AGR (%), and CAGR (%), 2018 - 2029
  • Table 4.2 U.S. Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2018 - 2029
  • Table 4.3 Canada Generic Drugs Market Value ($bn), AGR (%), CAGR (%), 2018 - 2029
  • Table 5.1 Europe Generic Drugs Market: by Country Value ($bn), AGR (%) and CAGR (%) 2018- 2029
  • Table 5.2 Germany Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2018 - 2029
  • Table 5.3 U.K. Generic Drugs Market Value ($bn) and AGR (%) 2018 - 2029
  • Table 5.4 France Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2018 - 2029
  • Table 5.5 Italy Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2018 - 2029
  • Table 5.6 Spain Generic Drugs Market Value ($bn), AGR (%), and CAGR (%), 2018 - 2029
  • Table 6.1 India Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.2 Leading Drug Types in Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2018, 2023 & 2029
  • Table 6.3 China Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.4 Japan Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.5 Australia Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.6 South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.1 South Africa Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.2 Saudi Arabia Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.3 UAE Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 8.1 Brazil Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 8.2 Argentina Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 8.3 Mexico Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 9.1 Top Generic Drugs Manufacturers: Total Revenue ($bn), Generic Drugs Revenue ($bn) and Generic Share of Revenue (%), 2017 and 2018
  • Table 9.2 Teva: Company Overview
  • Table 9.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
  • Table 9.4 Teva Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 9.5 Novartis: Overview
  • Table 9.6 Novartis/Sandoz: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
  • Table 9.7 Novartis/Sandoz Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 9.8 Mylan: Company Overview
  • Table 9.9 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2012-2018
  • Table 9.10 Mylan: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 9.11 Pfizer: Company Overview
  • Table 9.12 Pfizer (Greenstone): Historical 'Established Products' Drugs Sales ($bn) and AGR (%), 2014-2018
  • Table 9.13 Pfizer: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 9.14 Hospira: Company Overview
  • Table 9.15 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015
  • Table 9.16 Abbott: Company Overview
  • Table 9.17 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
  • Table 9.18 Abbott: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 9.19 Sun Pharmaceuticals: Company Overview
  • Table 9.20 Sun Pharma: Historical Generic Drugs Sales ($bn), 2014-2018
  • Table 9.21 Sun Pharma Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 9.22 Aspen: Company Overview
  • Table 9.23 Aspen: Historical Revenue ($bn, bn Rand) and AGR (%), 2014-2018
  • Table 9.24 Aspen Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 9.25 Fresenius Kabi: Company Overview
  • Table 9.26 Fresenius Kabi: Historical Generic Drugs Sales ($bn), 2014-2018
  • Table 9.27 Fresenius Kabi: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 9.28 Sanofi: Company Overview
  • Table 9.29 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
  • Table 9.30 Sanofi Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 9.31 Dr. Reddy's Laboratories Limited: Company Overview
  • Table 9.32 Dr. Reddy's: Historical Generic Drugs Sales ($bn) and AGR (%), 2015-2017
  • Table 9.33 Dr. Reddy's Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2029
  • Table 9.34 Apotex, Inc.: Company Overview
  • Table 10.1 SWOT Analysis of the Generic Drugs Market
  • Table 11.1 Global Generic Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2018, 2023 and 2029
  • Table 11.2 Top Generic Drug Manufacturers: Generic Drugs Revenue ($bn) and Market Share (%), 2018
  • Table 11.3 Global Generic Drugs Market Forecast: Revenue ($bn) by Regional Markets, 2018, 2023 and 2029

List of Figures

  • Figure 1.1 Global Generic Drugs Market Segmentation
  • Figure 2.1 EU Data Exclusivity for Generics: Possible Scenarios, 2018
  • Figure 3.1 The Global Generic Drugs Market Size: Revenue ($bn) by Regional Markets, 2018
  • Figure 3.2 The Global Generic Drugs Market Size: Revenue ($bn) by Regional Markets, 2023
  • Figure 3.3 The Global Generic Drugs Market Size: Revenue ($bn) by National Markets, 2018
  • Figure 3.4 The Global Generic Drugs Market Size: Revenue ($bn) by National Markets, 2023
  • Figure 3.5 Global Generic Drugs Market Forecast: ($bn) and AGR (%), 2018-2029
  • Figure 3.6 The Global Generic Drugs Market: Market Share (%) by Region, 2018
  • Figure 3.7 The Global Generic Drugs Market: Market Share (%) by Region, 2023
  • Figure 3.8 The Global Generic Drugs Market: Market Share (%) by Region, 2029
  • Figure 3.9 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2018-2023
  • Figure 3.10 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2023-2029
  • Figure 3.11 The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2018-2029
  • Figure 3.12 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2018
  • Figure 3.13 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2023
  • Figure 3.14 The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2029
  • Figure 3.15 The Global Generic Drugs Market Drivers & Restraints
  • Figure 4.1 North America Generic Drugs Market Drivers and Restraints
  • Figure 4.2 North America Generic Drugs Market: by Country Value ($bn) and AGR (%) 2018 - 2029
  • Figure 4.3 U.S. Generic Drugs Market Value ($bn) and AGR (%) 2018 - 2029
  • Figure 4.4 Canada Generic Drugs Market Value ($bn) and AGR (%) 2018 - 2029
  • Figure 4.5 North America Generic Drugs Market, % Country Share, 2018
  • Figure 4.6 North America Generic Drugs Market, % Country Share, 2023
  • Figure 4.7 North America Generic Drugs Market, % Country Share, 2029
  • Figure 5.1 Europe Generic Drugs Market: by Country Value ($ bn) and AGR (%) 2018 - 2029
  • Figure 5.2 Germany Generic Drugs Market Value ($bn) and AGR (%) 2018 - 2029
  • Figure 5.3 UK Generic Drugs Market Value ($bn) and AGR (%) 2018 - 2029
  • Figure 5.4 France Generic Drugs Market Value ($bn) and AGR (%) 2018 - 2029
  • Figure 5.5 Italy Generic Drugs Market Value ($bn) and AGR (%) 2018 - 2029
  • Figure 5.6 Spain Generic Drugs Market Value ($bn) and AGR (%) 2018 - 2029
  • Figure 5.7 Europe Generic Drugs Market, % Country Share, 2018
  • Figure 5.8 Europe Generic Drugs Market, % Country Share, 2023
  • Figure 5.9 Europe Generic Drugs Market, % Country Share, 2029
  • Figure 6.1 Asia-Pacific Generic Drugs Market Forecast: Revenue ($bn), 2018-2029
  • Figure 6.2 India Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.3 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2018
  • Figure 6.4 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2023
  • Figure 6.5 Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2029
  • Figure 6.6 China Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.7 Japan Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.8 Australia Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 6.9 South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2018-2029
  • Figure 6.10 Asia-Pacific Generic Drugs Market, % Country Share, 2018
  • Figure 6.11 Asia-Pacific Generic Drugs Market, % Country Share, 2023
  • Figure 6.12 Asia-Pacific Generic Drugs Market, % Country Share, 2029
  • Figure 7.1 Middle East & Africa Generic Drugs Market Forecast: Revenue ($bn), 2018-2029
  • Figure 7.2 South Africa Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.3 Saudi Arabia Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.4 UAE Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.5 Middle East & Africa Generic Drugs Market, % Country Share, 2018
  • Figure 7.6 Middle East & Africa Generic Drugs Market, % Country Share, 2023
  • Figure 7.7 Middle East & Africa Generic Drugs Market, % Country Share, 2029
  • Figure 8.1 Latin America Generic Drugs Market Forecast: Revenue ($bn), 2018-2029
  • Figure 8.2 Brazil Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 8.3 Argentina Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 8.4 Mexico Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 8.5 Latin America Generic Drugs Market, % Country Share, 2018
  • Figure 8.6 Latin America Generic Drugs Market, % Country Share, 2023
  • Figure 8.7 Latin America Generic Drugs Market, % Country Share, 2029
  • Figure 9.1 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2017
  • Figure 9.2 Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2018
  • Figure 9.3 Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
  • Figure 9.4 Teva Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 9.5 Novartis/Sandoz: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
  • Figure 9.6 Novartis/Sandoz Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 9.7 Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2012-2018
  • Figure 9.8 Mylan: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 9.9 Pfizer: Historical 'Established Products' Drugs Sales ($bn) and AGR (%), 2014-2018
  • Figure 9.10 Pfizer Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 9.11 Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015
  • Figure 9.12 Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
  • Figure 9.13 Abbott Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 9.14 Sun Pharma: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
  • Figure 9.15 Sun Pharma Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 9.16 Aspen: Historical Revenue ($bn) and AGR (%), 2014-2018
  • Figure 9.17 Aspen: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 9.18 Fresenius Kabi: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
  • Figure 9.19 Fresenius Kabi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 9.20 Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2018
  • Figure 9.21 Sanofi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 9.22 Dr. Reddy's: Historical Generic Drugs Sales ($bn) and AGR (%), 2015-2017
  • Figure 9.23 Dr. Reddy's Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2016-2029
  • Figure 10.1 Porter's Five Force Analysis of the Global Generic Drugs Market, 2018
  • Figure 11.1 Global Generic Drugs Market Forecast: Revenue ($bn), 2018, 2023 and 2029

Companies Listed

  • Abbott Laboratories
  • AbbVie
  • Able Labs
  • Aché
  • Actavis
  • Agila Specialties
  • Akron Pharmaceuticals
  • Alkem Laboratories
  • Allergan
  • Amgen
  • Anterios
  • Arcolab
  • ASKA Pharmaceuticals
  • Aspen
  • AstraZeneca
  • Aurobindo
  • Auspex Pharmaceuticals
  • Baxter International
  • Bayer
  • Bedford Laboratories
  • Bergamo
  • Biocon
  • Bioniche Pharma Holdings
  • Caraco
  • CFR Pharmaceuticals
  • Cipla
  • Claris
  • Daiichi Sankyo
  • Dalim BioTech
  • Dr. Reddy's Laboratories
  • Ebewe Pharma
  • Eden Biopharm Group
  • Elder Pharmaceuticals
  • Eli Lilly Company
  • Elyson Pharmaceuticals
  • EMS Sigma Pharma
  • Eon Labs
  • Eurofarma Laboratories
  • Farmacias Similares
  • Filaxis
  • Fougera Pharmaceuticals
  • Fresenius Kabi
  • Fuji Pharma
  • Gavis Pharmaceuticals
  • Grupo Sanborns
  • Grupo Uriach
  • GlaxoSmithKline (GSK)
  • Hexal
  • Hisun-Pfizer Pharmaceuticals
  • Hospira Healthcare India Private Limited
  • Ilsung Pharmaceuticals
  • Imperial Credit Private Limited
  • InnoPharma
  • Itero Biopharmaceuticals
  • Janssen Pharmaceuticals
  • Johnson & Johnson
  • King Pharmaceuticals
  • Kmart
  • KMS Pharmaceutical
  • Kowa Pharmaceuticals
  • Labesfal
  • Laboratorio Sanderso
  • Laboratorios Best
  • Lek
  • Lundbeck
  • Lupin Pharmaceuticals
  • Mayne Pharma
  • Meda AB
  • Medley
  • Merck KGaA's
  • Momenta
  • MSD
  • Mylan
  • Natco
  • Nexus Pharmaceuticals
  • Nichi-Iko
  • Nippon Chemiphar
  • Novartis (Sandoz)
  • Novo Nordisk
  • Orchid Chemicals & Pharmaceuticals
  • Oriel Therapeutics
  • Patriot Pharma
  • Pfizer
  • Pharmacia
  • Piramal
  • PT Ethica Industry Farmasi
  • PT Soho Global Health
  • Ranbaxy
  • Ratiopharm
  • Ribbon
  • Rimsa
  • Roche
  • Sabex
  • Sandoz
  • Sanofi
  • Sawai Pharmaceuticals
  • Servier
  • Sigma Pharmaceuticals
  • Solvay Pharmaceuticals
  • St. Jude Medical
  • STADA Arzneimittel
  • Strides Arcolab
  • Sun Pharma
  • Synthélabo
  • Taisho Pharmaceutical
  • Taiyo Pharmaceuticals
  • Takeda Pharmaceutical Company Limited
  • Target
  • Teuto Brasileiro
  • Teva
  • Torrent Pharmaceuticals
  • Towa
  • Walmart
  • Warner Chilcott
  • Watson Pharmaceuticals
  • Werner - Lambert
  • Wockhardt
  • Wyeth
  • Zentiva
  • Zhejiang Hisun Pharmaceutical
  • Zydus Cadila

List of Organisations Mentioned in the Report

  • Agência Nacional de Vigilância Sanitária
  • American Pharmaceutical Association
  • Blue Cross Blue Shield Association
  • British Generic Manufacturers Association
  • Caisse Nationale de l'Assurance Maladie
  • Center for Drug Evaluation and Research
  • Centers for Medicare and Medicaid
  • Competition Commission of India
  • European Generic Medicines Association
  • European Medicines Agency
  • Italian Generics Association, Assogenerici
  • Medical Technology Association of Australia
  • Ministry of Health, Labour and Welfare
  • National Health Service
  • National Health Surveillance Agency
  • Pharmaceuticals and Medical Devices Agency
  • Servicio Sanitario Nazionale
  • US Federal Trade Comission
  • US Generic Pharmaceutical Association
目次
Product Code: PHA0438

The generic drugs market is estimated to have reached $257.3bn in 2018 and is expected to grow at a CAGR of 8.8% in the first half of the forecast period. Asia-Pacific held 31% of the generic drugs market in 2018.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 246-page report you will receive 66 tables and 84 figures- all unavailable elsewhere.

The 246-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Generic Drugs Market forecasts from 2019-2029
  • Generic Drugs Market forecasts from 2019-2029 by Regional and National Market:
  • North America: U.S., Canada
  • Europe: Germany, France, UK, Italy, Spain, Rest of Europe
  • Asia-Pacific: Japan, China, Australia, South Korea, India, Rest of Asia-Pacific
  • Middle East & Africa: South Africa, Saudi Arabia, UAE, Rest of Middle east & Africa
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America

image1

  • Profiles and generic drugs revenue forecasts from 2019-2029 of these selected leading companies:
  • Abbott
  • Apotex
  • Aspen
  • Dr. Reddy's Laboratories Limited
  • Fresenius Kabi
  • Mylan
  • Novartis
  • Pfizer
  • Sanofi
  • Sun Pharma
  • Teva
  • Qualitative analysis of the generic drugs market:
  • SWOT Analysis of the generic drugs market
  • Porter's Five Forces Analysis of the generic drugs market
  • Discussion on factors that drive and restrain the generic drugs market
  • Key Questions Answered by This Report:
  • How is the global market for generic drugs evolving?
  • What are the major factors driving and restraining the generic drugs market dynamics?
  • What were the market shares of the leading national markets in the global generic drugs market in 2018?
  • How will each of these national markets grow over the forecast period and how much revenue will these markets account for by 2029?
  • How will the market shares for each of the national markets develop from 2018 to 2029?
  • Which particular national markets will be the main drivers of growth in the global market for generics from 2018 to 2029?
  • How will political and regulatory factors influence the regional markets and submarkets?
  • What are the predictions for partnerships, consolidation for existing players and the potential prospects for new market entrants?
  • How will the industry sector evolve as legislations around patents and patent expiries change during the period between 2018 and 2029?

Visiongain's study is intended for anyone requiring commercial analyses for the Generic Drugs Market. You find data, trends and predictions.

Buy our report today Generic Drugs Market Forecast 2019-2029: Growth in Leading Regional and National Markets - North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico, Teva, Novartis, Mylan, Pfizer, Abbott, Sun Pharma, Aspen, Fresenius Kabi, Sanofi, Dr. Reddy's Laboratories Limited, Apotex.

Visiongain is a trading partner with the US Federal Government

Table of Contents

1. Report Overview

  • 1.1 Global Generic Drugs: Market Overview
  • 1.2 Global Generic Drugs Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is this Report for?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2. An Introduction to Generic Drugs

  • 2.1 An Introduction to the Rise of Generic Drugs
  • 2.2 What Are Generic Drugs?
    • 2.2.1 Generic Active Ingredients
  • 2.3 A Brief Overview of the Pharmaceutical Industry
    • 2.3.1 Brief History of Generic Drugs
    • 2.3.2 The Hatch-Waxman Act: The Rise of Generics
  • 2.4 Demonstrating Bioequivalence: A Major Factor in Approving Generics
  • 2.5 Types of Generics - Authorised, Branded and Unbranded
  • 2.6 Complex Generics
  • 2.7 Classification of Generic Drugs Markets
  • 2.8 Is Generic Substitution Bad News for Big Pharma Business?
    • 2.8.1 The 'Ever greening' of Pharmaceutical Products
  • 2.9 Regulation of Generic Drugs
    • 2.9.1 Regulation in the US
      • 2.9.1.1 Obtaining FDA Approval: NDAs and ANDAs
      • 2.9.1.2 The Hatch-Waxman Act Title I: Promotion of Generic Drugs
      • 2.9.1.3 The Hatch-Waxman Act Title II: Incentives for the Branded Industry
      • 2.9.1.4 How Hatch-Waxman Act Impacted the US Pharmaceuticals Market?
      • 2.9.1.5 How Market Entry Timing Influences Product Success
    • 2.9.2 Regulation in Europe
      • 2.9.2.1 EU Marketing Approval Procedures
      • 2.9.2.2 The 8+2+1 Rule: EU Data Exclusivity
      • 2.9.2.3 Supplementary Protection Certificates
      • 2.9.2.4 Variation in Drug Development Regulations between European Countries
      • 2.9.2.5 The Move towards Harmonisation of Standards
      • 2.9.2.6 The Impact of Europe's Unitary Patent System on Generic Drugs
      • 2.9.2.7 In or Out: Unitary Patent Strategy for European Generic Drug Manufacturing
    • 2.9.3 Regulation in Japan
    • 2.9.4 Regulation in China
  • 2.10 Compulsory Licensing
  • 2.11 Market Definition and Scope of this Report
    • 2.11.1 Market Sizing and Revenue Reporting

3. Generic Drugs Market Forecast 2019-2029

  • 3.1 The Global Generic Drugs Market: Market Overview
    • 3.1.1 Segmenting the Global Generic Drugs Market
  • 3.2 The Rise of the Global Generic Drugs Market in 2019
  • 3.3 The Global Generic Drugs Market: Sales Forecast 2019-2029
  • 3.4 Generic Drugs: Regional Market Forecast: 2019-2029
    • 3.4.1 Changes in Generic Drug Regional Market Shares 2019-2029
  • 3.5 National Markets that Will Drive Generic Drugs Growth
  • 3.6 Changes in Market Shares by National Market 2019-2029
  • 3.7 Drivers and Restraints for the Global Generic Drugs Market 2019-2029

4. North America Generic Drugs Market, 2019-2029

  • 4.1 Generic Drugs in the North America: Market Overview
    • 4.1.1 The Hatch-Waxman Act and Its Ongoing Effects
    • 4.1.2 Consolidation in the Drug Development and Supply Chain Driving North America Generics
  • 4.2 North America Generic Drugs Market: Drivers and Restraints 2019-2029
  • 4.3 North America Generic Drugs Market Forecast: 2019-2029
  • 4.4 Leading Companies Operating within the North America Generic Drugs Market
    • 4.4.1 Increasing Acceptance of Generics amongst Consumers
    • 4.4.2 Affordable Care Act: Expanding Medicare Coverage
  • 4.5 North America Generic Drugs Market - Strategic Analysis
    • 4.5.1 Will Biosimilars Dictate the Future of the US Generics Market?
    • 4.5.2 The Backlog of ANDA Applications
    • 4.5.3 The Generic Drug User Fee Amendments (GDUFA)
    • 4.5.4 Shortages of Generic Drugs Will Restrain the Market
    • 4.5.5 The Anti-Competitive 'Pay for Delay' Effect
  • 4.6 US Generic Drugs Market: A Range of Factors Contributing to Growth
  • 4.7 Canada Generic Drugs Market: A Range of Factors Contributing to Growth
  • 4.8 North America Generic Drugs Market: Market Share Analysis

5. Europe Generic Drugs Market, 2019-2029

  • 5.1 Generic Drugs in the Europe: Market Overview
    • 5.1.1 Why Growth in Some Markets is Being Hindered?
    • 5.1.2 Predominant Pricing Systems and Generic Penetration in European Markets
      • 5.1.2.1 Lower Patient Co-Payments Drive Demand for Generics
      • 5.1.2.2 The Effects of Tendering for Generic Medicines
    • 5.1.3 Will Europe Move towards Free-Pricing Systems?
    • 5.1.4 Challenges in the European Regulatory Environment
    • 5.1.5 Ending Anti-Competitive 'Pay for Delay' Tactics in Europe
    • 5.1.6 FDA and EMA Joint Data Sharing and Inspections
  • 5.2 Europe Generic Drugs Market Forecast: 2019-2029
  • 5.3 Germany Generic Drugs Market: New Reforms to Medicinal Pricing May Impact Market Entry
  • 5.4 UK Generic Drugs Market: A Mature Market with Growth Potentials
    • 5.4.1 Cost Pressures and Demand-Side Policies Drive UK Generic Penetration
  • 5.5 France Generic Drugs Market: Healthcare Reforms Impacting on Market Growth
  • 5.6 Italy Generic Drugs Market: Branded Generics Hindering Overall Growth
    • 5.6.1 The Tightening of Italy's Patent Legislations
    • 5.6.2 The Italian Healthcare System - A Tale of Falling Budgets
  • 5.7 Spain Generic Drugs Market: Room for Growth
    • 5.7.1 Cost-Containment Measures Helping to Boost Generic Drug Use
  • 5.8 Europe Generic Drugs Market: Market Share Analysis

6 Asia-Pacific Generic Drugs Market, 2019-2029

  • 6.1 Generic Drugs in the Asia-Pacific Market: Market Overview
  • 6.2 Indian Generic Drugs Market: Regulatory Failures Hindering Sales Growth
    • 6.2.1 Leading Companies in the Indian Generic Drugs Market
    • 6.2.2 Indian Generic Drugs Market: Sales Forecast 2019-2029
    • 6.2.3 The Reforms to India's Drug Prices Control Order and Its Likely Effects on Generic Drugs Revenues
    • 6.2.4 Expansion of the National Healthcare Coverage Increases the Need for Generics
    • 6.2.5 Has Recent Manufacturing Quality Failures Dented India's Generics Growth?
  • 6.3 Chinese Generic Drugs Market: Domestic Companies Dominate the Market Landscape
    • 6.3.1 The Major Drivers of Growth in the Chinese Generics Market
    • 6.3.2 Chinese Generic Drugs Market: Sales Forecast 2019-2029
    • 6.3.3 Compulsory Licensing of Generic Drugs
    • 6.3.4 Expansion of Healthcare Coverage and Reimbursement
    • 6.3.5 The Impacts of Price Controls and the Anhui Model
  • 6.4 Japanese Generic Drugs Market: High Barriers to Entry
    • 6.4.1 Public Perception of Generics in Japan
    • 6.4.2 Japanese Generic Drugs Market: Leading Companies
    • 6.4.3 Government Initiatives Driving Generic Penetration
    • 6.4.4 Japanese Attitudes to Generic Drugs
    • 6.4.5 Japanese Generic Drugs Market: Sales Forecast 2019-2029
  • 6.5 Australia Generic Drugs Market: Increased Market Access Supports the Market Growth
    • 6.5.1 Australia Generic Drugs Market: Sales Forecast 2019-2029
  • 6.6 South Korean Generic Drugs Market: Expected to Continue Its Trend of Growth
    • 6.6.1 Pharmaceutical Price Controls and Measures Being Implemented in South Korea
    • 6.6.2 KORUS FTA: The Free Trade Agreement between South Korea and the US
    • 6.6.3 The Free Trade Agreement between Korea and the European Union
    • 6.6.4 South Korean Generic Drugs Market: Sales Forecast 2019-2029
  • 6.7 Asia-Pacific Generic Drugs Market: Market Share Analysis

7 Middle East & Africa Generic Drugs Market, 2019-2029

  • 7.1 Generic Drugs in the Middle East & Africa Market: Market Overview
  • 7.2 South Africa Generic Drugs Market:
    • 7.2.1 South Africa Generic Drugs Market: Sales Forecast 2019-2029
  • 7.3 Saudi Arabia Generic Drugs Market:
    • 7.3.1 Saudi Arabia Generic Drugs Market: Sales Forecast 2019-2029
  • 7.4 UAE Generic Drugs Market:
    • 7.4.1 UAE Generic Drugs Market: Sales Forecast 2019-2029
  • 7.5 Middle East & Africa Generic Drugs Market: Market Share Analysis

8. Latin America Generic Drugs Market, 2019-2029

  • 8.1 Generic Drugs in the Latin American Market: Market Overview
  • 8.2 Brazil Generic Drugs Market:
    • 8.2.1 Brazil Generic Drugs Market: Sales Forecast 2019-2029
  • 8.3 Argentina Generic Drugs Market:
    • 8.3.1 Argentina Generic Drugs Market: Sales Forecast 2019-2029
  • 8.4 Mexico Generic Drugs Market:
    • 8.4.1 Mexico Generic Drugs Market: Sales Forecast 2019-2029
  • 8.5 Latin America Generic Drugs Market: Market Share Analysis

9 Leading Companies in the Generic Drugs Market

  • 9.1 Generic Drugs: Continuous Expansion to Rival
    • 9.1.1 The Leading Companies in the Global Generics Market
  • 9.2 Teva Pharmaceuticals Industries Limited
    • 9.2.1 Teva: Historical Financial and Performance Analysis, 2014-2018
    • 9.2.2 Teva Generic Drugs Sales Forecast 2019-2029
    • 9.2.3 Teva acquired Allergan's Generic Business Segment - Actavis Generic
      • 9.2.3.1 Further Entry into the Japanese Generics Market
    • 9.2.4 Teva: Generic Drugs Portfolio Analysis
      • 9.2.4.1 High-Value Generics to Drive Teva's Generics Growth?
      • 9.2.4.2 The Shift towards Innovation
      • 9.2.4.3 Copaxone Leads Teva's Moving Focus
      • 9.2.4.4 The Threat of Generic Erosion to Teva's Products
      • 9.2.4.5 Teva: What Future Moves Could We Expect?
  • 9.3 Novartis
    • 9.3.1 Novartis/Sandoz: Historical Financial and Performance Analysis, 2014-2018
    • 9.3.2 Novartis/Sandoz Generic Drugs Sales Forecast 2019-2029
    • 9.3.3 Novartis/Sandoz Generic Drugs Portfolio Analysis, 2017-2018
      • 9.3.3.1 Emphasis on Difficult-to-Manufacture Products
      • 9.3.3.2 What Does the Future Hold for Novartis' Generic Drugs Business
  • 9.4 Mylan
    • 9.4.1 Mylan: Historical Financial and Performance Analysis, 2012-2018
    • 9.4.2 Mylan Generic Drugs Sales Forecast 2019-2029
    • 9.4.3 Mylan: Recent Developments
      • 9.4.3.1 Acquisition of Meda AB
      • 9.4.3.2 Acquisition of Abbott's Generic Business
      • 9.4.3.3 Mylan's Growth in Manufacturing Capacity
      • 9.4.3.4 Mylan Acquires Rights to GSK's Advair, Diskus and Seretide
      • 9.4.3.5 The Race to Market Copaxone Generics
      • 9.4.3.6 Strategic Acquisition of Agila Expands Mylan's Injectables Business
      • 9.4.4 Mylan's Collaborative Efforts
      • 9.4.4.1 Biosimilar Collaboration with India's Biocon
      • 9.4.4.2 Biosimilar Collaborations with Momenta
      • 9.4.4.3 What Does the Future Hold for Mylan's Generic Drugs Business?
  • 9.5 Pfizer
    • 9.5.1 Pfizer: Historical Financial and Performance Analysis, 2014-2016
    • 9.5.2 Pfizer's Restructuring Strategy
    • 9.5.3 Pfizer's Done Deal with Hospira
    • 9.5.4 Pfizer Generic Drugs Sales Forecast 2019-2029
    • 9.5.5 Hospira: A Brief Overview of Operations
    • 9.5.6 Hospira: Historical Financial and Performance Analysis 2011-2015
    • 9.5.7 Hospira: Recent Developments
      • 9.5.7.1 Hospira's Expansion through Strategic Acquisitions
      • 9.5.7.2 Hospira: Manufacturing Concerns and Remediation Efforts
    • 9.5.8 Future Prospects for Pfizer's Generic Business
      • 9.5.8.1 The Pfizer-Allergan Deal Falls Through
      • 9.5.8.2 Activities of Allergan (Actavis) Prior to Mega-Merger
      • 9.5.8.3 Actavis' Work on Biosimilars
  • 9.6 Abbott
    • 9.6.1 Abbott: Historical Financial and Performance Analysis, 2014-2016
    • 9.6.2 Abbott Generic Drugs Sales Forecast 2019-2029
    • 9.6.3 Abbott: Recent Developments
      • 9.6.3.1 Abbott acquired St. Jude Medical
      • 9.6.3.2 Abbott after the Spin-Off of AbbVie - The Established Products Business Segment
      • 9.6.3.3 Acquisition of Solvay Pharmaceuticals and Piramal Healthcare Solutions
      • 9.6.3.4 Acquisition of CFR Pharmaceuticals Opens New Markets
    • 9.6.4 What Does the Future Hold for Abbott's Generic Drugs Business?
    • 9.7 Sun Pharma
    • 9.7.1 Sun Pharma's Business Areas
    • 9.7.2 Sun Pharma: Historical Financial and Performance Analysis, 2014-2018
    • 9.7.3 Sun Pharma Generic Drugs Sales Forecast 2019-2029
    • 9.7.4 Sun Pharma-Ranbaxy Acquisition
  • 9.8 Aspen
    • 9.8.1 Aspen: Historical Financial and Performance Analysis, 2014-2018
    • 9.8.2 Aspen Generic Sales Forecast 2019-2029
    • 9.8.3 Aspen: Recent Developments
      • 9.8.3.1 Aspen Acquires Merck MSD's Dutch API Plant
      • 9.8.3.2 Acquisition of GSK's Anti-Thrombosis Brands
      • 9.8.3.3 Future Outlook for Aspen's Generic Business
  • 9.9 Fresenius Kabi
    • 9.9.1 Fresenius Kabi: Historical Financial and Performance Analysis, 2014-201
    • 9.9.2 Fresenius Kabi Generic Drugs Sales Forecast 2019-2029
    • 9.9.3 InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisition
    • 9.9.4 Fresenius Kabi's Joint Venture with PT Soho Global Health
    • 9.9.5 Future Prospects for Fresenius Kabi's Generics Business
  • 9.10 Sanofi
    • 9.10.1 Sanofi: Historical Financial and Performance Analysis, 2014-2018
    • 9.10.2 Sanofi Generic Sales Forecast 2019-2029
    • 9.10.3 Sanofi's Response to Lantus Competition
    • 9.10.4 Emerging Market Acquisitions
    • 9.10.5 Future Prospects for Sanofi's Generics Business
  • 9.11 Dr. Reddy's Laboratories Limited
    • 9.11.1 Dr. Reddy's: Historical Financial and Performance Analysis, 2015-2017
    • 9.11.2 Dr. Reddy's Generic Sales Forecast 2019-2029
    • 9.11.3 Dr. Reddy's launched generic Azacitidine for Injection in the Canadian Market
    • 9.11.4 The company acquired Imperial Credit Private Limited, a Non-Banking Finance Company
    • 9.11.5 Dr. Reddy's expanded its operations in the European region
  • 9.12 Apotex, Inc.
    • 9.12.1 Apotex expanded its manufacturing facilities in the U.S.
    • 9.12.2 Apotex launched first Generic Version of Merck's Nasonex

10. Qualitative Analysis of the Generic Drugs Market

  • 10.1 Market Factors Influencing the Global Generic Drugs Market
  • 10.2 SWOT Analysis of the Global Generic Drugs Market
    • 10.2.1 Strengths
      • 10.2.1.1 Improving Clarity around Regulatory Processes
      • 10.2.1.2 The Continuous Government Support for Generic Manufacturers - Precursors for Innovation
      • 10.2.1.3 Higher Pace of Growth Compared with Innovative Pharma
      • 10.2.1.4 Globalisation and Its Impact on Manufacturing Capabilities
    • 10.2.2 Weaknesses
      • 10.2.2.1 Safety and Quality Concerns in the Manufacturing Process
      • 10.2.2.2 The Non-Uniformity of Excipients
      • 10.2.2.3 The Uncertainty around Patent Extensions and Exclusivities
      • 10.2.2.4 Sceptical Physicians and the Negative Consumer Perception of Generics
      • 10.2.2.5 Inefficiencies in Certain Regulatory Approval Processes
    • 10.2.3 Opportunities
      • 10.2.3.1 Higher Value Biosimilars and Branded Generics
      • 10.2.3.2 Patent Expiries Creating Opportunities
      • 10.2.3.3 Changing Socio-Economic Conditions Impacting Generic Drugs Demand
      • 10.2.3.4 Emerging Markets - Expected to Drive Generics Volume Growth over Time
    • 10.2.4 Threats
      • 10.2.4.1 Government Cost-Cutting Initiatives Impacting on Generic Drugs Prices
      • 10.2.4.2 The Complexity Surrounding Patents and Patent Expiries
      • 10.2.4.3 Pharmacies and Healthcare Payer Consolidations
      • 10.2.4.4 Possible Impacts of a Declining Patent Pool
  • 10.3 Porter's Five Force Analysis of the Global Generic Drugs Market
    • 10.3.1 Power of Buyers: Medium
    • 10.3.2 Power of Suppliers: Low
    • 10.3.3 Rivalry among Competitors: High
    • 10.3.4 Threat of New Entrants: High
    • 10.3.5 Threat of Substitutes: Low

11. Conclusion

  • 11.1 Overview of Current Market Conditions and Market Forecast, 2019-2029
  • 11.2 Generic Drugs as a Strategic Tool in Healthcare
  • 11.3 Major Drivers of Growth for Generic Drugs
  • 11.4 The Regulatory Landscape for Generic Drugs
  • 11.5 Leading Generic Drug Manufacturers
  • 11.6 Future Outlook for the Leading Regions within the Global Generic Drugs Market, 2019-2029
  • 11.7 What Does the Future Hold for the Global Generic Drugs Market?

Appendices

  • Glossary
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
Back to Top